» Articles » PMID: 37791041

Asthma and COVID-19 Outcomes: A Prospective Study in a Large Health Care Delivery System

Overview
Publisher Dove Medical Press
Date 2023 Oct 4
PMID 37791041
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Previous studies on the outcomes of asthma and COVID-19 have shown inconsistent results. This study aimed to elucidate the association between asthma and COVID-19 outcomes.

Methods: We conducted a prospective study with a large health plan to compare the incidence of COVID-19 infection, hospitalization and ICU admission in a cohort of 41,282 patients with asthma and a 1:1 age-, sex-, and race-ethnicity-matched cohort without asthma across the following pandemic periods: pre-Delta (03/01/2020 to 05/31/2021), Delta (06/01/2021 to 12/31/2021), and Omicron (01/01/2022 to 08/13/2022). Demographic factors, comorbidities, COVID-19 test results, inpatient utilization, and COVID-19 vaccination status were collected from electronic health records.

Results: Subjects with asthma were more likely than controls to undergo COVID-19 testing during the three pandemic periods and were less likely to test positive in the Omicron period (fully adjusted odds ratio=0.92; 95% CI=0.86-0.98; p=0.01). Relative to controls, patients with asthma had an increased risk of hospitalization for COVID-19 (fully adjusted hazard ratio=1.33; 95% CI=1.08-1.64; p=0.01) and borderline significant (p=0.05) higher rates of ICU admissions in the pre-delta period but not during the delta or Omicron periods. The increased risk of COVID-19 hospitalization associated with asthma was more pronounced in patients with severe asthma and in women compared with men. None of the associations were significantly modified by vaccination status.

Conclusion: Asthma was associated with a lower risk of COVID-19 infection but only during the Omicron period. Asthma was an independent risk factor for hospitalization for COVID-19 in the pre-delta period and this association was stronger for severe asthma and in women.

Citing Articles

Clinical features in patients with COVID-19 treated with biologics for severe asthma.

Numata T, Okuda K, Miyagawa H, Minagawa S, Ishikawa T, Hara H J Allergy Clin Immunol Glob. 2024; 3(2):100219.

PMID: 38375460 PMC: 10875260. DOI: 10.1016/j.jacig.2024.100219.

References
1.
Mendes N, Jara C, Mansour E, Araujo E, Velloso L . Asthma and COVID-19: a systematic review. Allergy Asthma Clin Immunol. 2021; 17(1):5. PMC: 7787409. DOI: 10.1186/s13223-020-00509-y. View

2.
Ganna A, Reilly M, de Faire U, Pedersen N, Magnusson P, Ingelsson E . Risk prediction measures for case-cohort and nested case-control designs: an application to cardiovascular disease. Am J Epidemiol. 2012; 175(7):715-24. PMC: 3324433. DOI: 10.1093/aje/kwr374. View

3.
Lian M, Struthers J, Liu Y . Statistical Assessment of Neighborhood Socioeconomic Deprivation Environment in Spatial Epidemiologic Studies. Open J Stat. 2016; 6(3):436-442. PMC: 4940131. DOI: 10.4236/ojs.2016.63039. View

4.
Chhiba K, Patel G, Vu T, Chen M, Guo A, Kudlaty E . Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020; 146(2):307-314.e4. PMC: 7295471. DOI: 10.1016/j.jaci.2020.06.010. View

5.
Cao Y, Chen S, Chen X, Zou W, Liu Z, Wu Y . Global trends in the incidence and mortality of asthma from 1990 to 2019: An age-period-cohort analysis using the global burden of disease study 2019. Front Public Health. 2022; 10:1036674. PMC: 9723391. DOI: 10.3389/fpubh.2022.1036674. View